A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
PD-L1 Lung (Atezolizumab), IHC
Test Code94480
CPT Codes
88360
Preferred Specimen
Formalin-fixed paraffin-embedded tissue, NSCLC collected in an IHC Specimen transport kit
Other Acceptable Specimens
5 unstained charged(+) slides collected in an IHC specimen transport kit
Instructions
FFPE: State any other type of fixative used.
A pathology report which includes the paraffin block number, and both macroscopic and microscopic evaluation and diagnosis, should be sent with the specimen.
A pathology report which includes the paraffin block number, and both macroscopic and microscopic evaluation and diagnosis, should be sent with the specimen.
Transport Temperature
Room temperature
Specimen Stability
Formalin-fixed paraffin embedded tissue
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable
Unstained charged(+) slides
Room temperature: 30 days
Refrigerated: 30 days
Frozen: Unacceptable
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable
Unstained charged(+) slides
Room temperature: 30 days
Refrigerated: 30 days
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Baked or melted slides • Previously stained slides • Cytospins • Tissue types other than lung cancer specimens • Cytology cell block • Decalcified specimens • Fixatives other than formalin
Methodology
Immunohistochemical Stain
Setup Schedule
A.M. Sets up 5 days a week.
Report Available
Reports in 3 to 5 days.
Clinical Significance
TECENTRIQ is the first FDA-approved anti-PD-L1 cancer immunotherapy which is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum- containing chemotherapy. Determining a patient's PD-L1 expression level can provide insight into the survival benefit that may be achieved from treatment with TECENTRIQ. PD-L1 expression in ≥50% tumor cells (TC) or ≥10% tumor-infiltrating immune cells (IC) (lymphocytes, macrophages, dendritic cells, and granulocytes) determined by VENTANA PD-L1 (SP-142) Assay/Quest PD-L1 Lung (Atezolizumab) in non-small cell lung cancer tissue may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).